The notices it replaced
- Reissues: PAR-24-173 NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
- 2 steps back: PAR-21-119 NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required)
- 3 steps back: PAR-18-683 NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required)
Who won it before
16 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,473,342 in first-year total cost, median $415,514.
Most frequent study sections
- Special Emphasis Panel[ZHL1 CSR-F (J2)]3
- Special Emphasis Panel[ZHL1 CSR-F (M1)]3
- Special Emphasis Panel[ZHL1 CSR-F (F2)]2
- NHLBI Single-Site and Pilot Clinical Trials Study Section[SSPT (MA)]1
- Special Emphasis Panel[ZHL1 CSR-B (F3)]1
Most frequent institutions
- WEILL MEDICAL COLL OF CORNELL UNIV4
- UNIVERSITY OF PENNSYLVANIA2
- AYUVIS RESEARCH, INC.1
- BOSTON CHILDREN'S HOSPITAL1
- CINCINNATI CHILDRENS HOSP MED CTR1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | CHERISH (duCHennE caRdiomyopathy mItigation Sglt2 inHibitor)1R61HL180327-01 · under PAR-24-173 | MARKHAM, LARRY W.SOSLOW, JONATHAN HARVEYSPURNEY, CHRISTOPHER FORE | INDIANA UNIVERSITY INDIANAPOLIS, IN | $444,838 | SSPT |
| 2024 | XFIT: An Exercise-based Frailty Intervention in Lung Transplant Candidates1R61HL169183-01A1 · under PAR-21-119 | SINGER, JONATHAN PAULSMITH, PATRICK JOSEY | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $452,181 | ZHL1 |
| 2024 | Gene Therapy for Alpha 1-Antitrypsin Deficiency1R61HL169190-01A1 · under PAR-21-119 | CRYSTAL, RONALD G | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $422,895 | ZHL1 |
| 2023 | A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung Transplantation1R61HL169189-01 · under PAR-21-119 | BYERS, DEREK EGELMAN, ANDREW ERICGOSS, CHARLESHACHEM, RAMSEY | WASHINGTON UNIVERSITY, MO | $371,405 | ZHL1 |
| 2023 | SGLT-inhibitors in patients with hypertrophic cardiomyopathy1R61HL164376-01A1 · under PAR-21-119 | DAY, SHARLENE M | UNIVERSITY OF PENNSYLVANIA, PA | $370,904 | ZHL1 |
| 2023 | A Personalized Surgical Approach for the Treatment of Children with Obstructive Sleep Apnea and Small Tonsils1R61HL162771-01A1 · under PAR-21-119 | LAM, DEREK J | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $332,149 | ZHL1 |
| 2023 | Phase-1 Healthy adult human safety and pharmacokinetic study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in at-risk pre-term infants1R61HL164372-01A1 · under PAR-21-119 | ACHARYA, SUCHISMITA | AYUVIS RESEARCH, INC., TX | $270,788 | ZHL1 |
| 2022 | Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients1R61HL158540-01A1 · under PAR-21-119 | CHAPMAN, HAROLD AMARTINEZ, FERNANDO JSPINO, CATHERINE A | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $453,796 | ZHL1 |
| 2022 | Transplanting Lungs from Uncontrolled Donation after Circulatory Death1R61HL156890-01A1 · under PAR-21-119 | MONTGOMERY, ROBERT AWALL, STEPHEN P | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $425,407 | ZHL1 |
| 2022 | Multi-center, randomized, controlled trial of the feasibility and safety of inhaled hydrogen gas during ECPR1R61HL164373-01 · under PAR-21-119 | KHEIR, JOHN NAGISLEEPER, LYNN A | BOSTON CHILDREN'S HOSPITAL, MA | $410,558 | ZHL1 |
| 2021 | A phase I trial of AdKCNH2-G628S gene therapy for post-op atrial fibrillation1R61HL158541-01 · under PAR-18-683 | DONAHUE, J KEVINMCMANUS, DAVID D. | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $418,750 | ZHL1 |
| 2021 | Human gene transfer & macrophage cell transplantation therapy of hereditary PAP (hPAP)1R61HL156888-01 · under PAR-18-683 | KRISCHER, JEFFREY PTRAPNELL, BRUCE C | CINCINNATI CHILDRENS HOSP MED CTR, OH | $410,607 | ZHL1 |
| 2020 | A Phase 1b Study of Inhaled CO for the Treatment of Sepsis-Induced ARDS1R61HL153011-01 · under PAR-18-683 | CHOI, AUGUSTINE MFREDENBURGH, LAURA ELIZABETH | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $452,945 | ZHL1 |
| 2020 | Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's Ataxia1R61HL151355-01 · under PAR-18-683 | CRYSTAL, RONALD GKAMINSKY, STEPHEN MICHAELWEINSAFT, JONATHAN W. | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $420,378 | ZHL1 |
| 2019 | Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia1R61HL147833-01 · under PAR-18-683 | HORNIK, CHRISTOPHLAUGHON, MATTHEW | DUKE UNIVERSITY, NC | $412,278 | ZHL1 |
| 2019 | Developing Oral LT3 Therapy for Heart Failure1R61HL146390-01 · under PAR-18-683 | CAPPOLA, ANNE RCAPPOLA, THOMAS P.CHIRINOS MEDINA, JULIO ALONSO | UNIVERSITY OF PENNSYLVANIA, PA | $403,463 | ZHL1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.